Health of "millions" threatened by HFC curbs, claims GlaxoWellcome
Pharmaceuticals giant GlaxoWellcome has claimed that controls on HFCs under the Kyoto Protocol on climate change could affect the health of "millions" of patients with respiratory illnesses who use metered dose inhalers (MDIs). Its £2 billion per year inhalers business is built largely around MDIs. But Swedish officials maintain that many patients could use alternative dry powder inhalers (DPIs) which do not contain HFCs.
Sign in to continue
Need to activate your subscription?
Already a subscriber
If you haven't already, activate your subscription here>>
Company Domain Access
If your company or university has a corporate subscription simply register your email address here to gain access